Evidence map›Paper›PMID 36737530›Full record

ArticleAnnals of surgical oncology2023

Timing of Chemotherapy and Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Immediate Reconstruction.

Kate R Pawloski, Marissa K Srour, Tracy-Ann Moo, Varadan Sevilimedu, Jonas A Nelson, Paula Garcia, Laurie J Kirstein, Monica Morrow, Audree B Tadros

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kate R PawloskiBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marissa K SrourBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tracy-Ann MooBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Varadan SevilimeduBiostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonas A NelsonPlastic and Reconstructive Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paula GarciaBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Laurie J KirsteinBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Monica MorrowBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Audree B TadrosBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tadrosa@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NIH/NCi Cancer Center Support Grant P30CA008748
6 · The paper itself

Abstract

introductionReceipt of chemotherapy is associated with decreased satisfaction after breast surgery, but whether timing as adjuvant versus neoadjuvant (NAC) affects patient-reported outcomes (PROs) is unclear. We examined associations between chemotherapy timing and PROs after breast-conserving surgery (BCS) and mastectomy with immediate reconstruction (M-IR).

methodsIn this retrospective cohort study of patients with stage I-III breast cancer undergoing chemotherapy between January 2017 and December 2019, we compared satisfaction with breasts (SABTR) and chest physical well-being (PWB-CHEST) between chemotherapy groups in BCS and M-IR cohorts. Median SABTR and PWB-CHEST scores (scale 0-100) were compared between chemotherapy groups at baseline and for 3 years postoperatively. Factors associated with SABTR and PWB-CHEST at 1 and 2 years were assessed with multivariable linear regression.

resultsOverall, 640 patients had BCS and 602 had M-IR; 210 (33%) BCS patients and 294 (49%) M-IR patients had NAC. Following BCS, SABTR was higher than baseline at all postoperative timepoints, whereas 3-year SABTR remained similar to baseline following M-IR, independent of chemotherapy timing. In both surgical cohorts, PWB-CHEST was lowest after NAC at 6 months compared with baseline but was similar to adjuvant counterparts by 3 years. NAC was not a statistically significant predictor of SABTR or PWB-CHEST in either surgical cohort on multivariable analysis.

conclusionsFor patients with breast cancer who require chemotherapy, neoadjuvant versus adjuvant timing does not impact long-term PROs in this study. These findings may inform shared decision making regarding the sequence of treatment in patients with operable disease.

Indexed as

Breast NeoplasmsMammaplastyFemaleHumansMastectomyMastectomy, SegmentalPatient Reported Outcome MeasuresRetrospective Studies

Identifiers

PMID36737530
PMCPMC11110643
OpenAlexW4319073132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.